keyword
MENU ▼
Read by QxMD icon Read
search

Radiopharmaceutical

keyword
https://www.readbyqxmd.com/read/28551301/hybrid-imaging-with-pet-mri-ready-for-clinical-routine
#1
EDITORIAL
Jiří Ferda
The introduction of integrated PET/MRI imaging combining full magnetic resonance imaging and positron emission tomography is a new milestone in tissue imaging. As usual innovations in clinical practice generate new dilemmas. The questions it poses are: when to use PET/MRI scanning, what radiopharmaceutical to use and how to optimize examination protocols. A range of new radiopharmaceuticals, in addition to 18F-fluorodeoxyglucose (18F-FDG), are now available for assessing and characterizing tissues.
May 9, 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28546335/radiopharmaceuticals-for-therapy
#2
Dao Le
No abstract text is available yet for this article.
May 25, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28545366/role-of-positron-emission-tomography-for-central-nervous-system-involvement-in-systemic-autoimmune-diseases-status-and-perspectives
#3
Daniele Mauro, Gaetano Barbagallo, Salvatore D'Angelo, Sannino Pasqualina, Saverio Naty, Caterina Bruno, Ignazio Olivieri, Rosa Daniela Grembiale, Francesco Ursini
In the last years, an increasing interest in molecular imaging has been raised by the extending potential of positron emission tomography (PET). The role of PET imaging, originally confined to the oncology setting, is continuously extending thanks to the development of novel radiopharmaceutical and to the implementation of hybrid imaging techniques, where PET scans are combined with computed tomography (CT) or magnetic resonance imaging(MRI) in order to improve spatial resolution. Early preclinical studies suggested that 18F-FDG PET can detect neuroinflammation; new developing radiopharmaceuticals targeting more specifically inflammation-related molecules are moving in this direction...
May 23, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28541775/cellular-response-to-exponentially-increasing-and-decreasing-dose-rates-implications-for-treatment-planning-in-targeted-radionuclide-therapy
#4
Jay H Solanki, Thomas Tritt, Jordan B Pasternack, Julia J Kim, Calvin N Leung, Jason D Domogauer, Nicholas W Colangelo, Venkat R Narra, Roger W Howell
The treatment of cancer using targeted radionuclide therapy is of interest to nuclear medicine and radiation oncology because of its potential for killing tumor cells while minimizing dose-limiting toxicities to normal tissue. The ionizing radiations emitted by radiopharmaceuticals deliver radiation absorbed doses over protracted periods of time with continuously varying dose rates. As targeted radionuclide therapy becomes a more prominent part of cancer therapy, accurate models for estimating the biologically effective dose (BED) or equieffective dose given in 2 fractions (EQD2α/β) will become essential for treatment planning...
May 25, 2017: Radiation Research
https://www.readbyqxmd.com/read/28540215/myocardial-flow-reserve-mfr-with-positron-emission-tomography-pet-computed-tomography-ct-clinical-impact-in-diagnosis-and-prognosis
#5
REVIEW
Maria Cecilia Ziadi
In recent years, radionuclide myocardial perfusion imaging (MPI) using positron emission tomography/computed tomography (PET/CT) has emerged as a robust tool for the diagnosis, risk stratification and management of patients with known or established coronary artery disease (CAD). Cardiac PET/CT imaging affords key advantages compared to single photon emission computed tomography (SPECT) that encompass: (I) improved diagnostic accuracy; (II) decreased radiation exposure due to the utilization of short-lived radiopharmaceuticals, and importantly; (III) the ability to quantify noninvasively myocardial blood flow (MBF) in absolute terms, that is in ml per minute per gram of tissue...
April 2017: Cardiovascular Diagnosis and Therapy
https://www.readbyqxmd.com/read/28536834/the-conflict-between-treatment-optimization-and-registration-of-radiopharmaceuticals-with-fixed-activity-posology-in-oncological-nuclear-medicine-therapy
#6
EDITORIAL
C Chiesa, K Sjogreen Gleisner, G Flux, J Gear, S Walrand, K Bacher, U Eberlein, E P Visser, N Chouin, M Ljungberg, M Bardiès, M Lassmann, L Strigari, M W Konijnenberg
No abstract text is available yet for this article.
May 24, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28536392/personalized-dosimetry-for-radionuclide-therapy-using-molecular-imaging-tools
#7
REVIEW
Michael Ljungberg, Katarina Sjögreen Gleisner
For treatment of systemic malignancies, when external radiation therapy is not applicable, radionuclide therapy can be an alternative. In this form of therapy, radionuclides are administered to the patient, often in a form where the radionuclide is labelled to a molecule that plays the active part in the localization of the tumor. Since the aim is to impart lethal damage to tumor cells while maintaining possible side-effects to normal tissues at tolerable levels, a proper and accurate personalized dosimetry should be a pre-requisite...
November 15, 2016: Biomedicines
https://www.readbyqxmd.com/read/28533634/estimation-of-whole-body-radiation-exposure-to-nuclear-medicine-personnel-during-synthesis-of-177-lutetium-labeled-radiopharmaceuticals
#8
Geetanjali Arora, Rajesh Mishra, Praveen Kumar, Madhav Yadav, Sanjana Ballal, Chandrasekhar Bal, Nishikant Avinash Damle
PURPOSE OF THE STUDY: With rapid development in the field of nuclear medicine therapy, radiation safety of the personnel involved in synthesis of radiopharmaceuticals has become imperative. Few studies have been done on estimating the radiation exposure of personnel involved in the radio labeling of (177)Lu-compounds in western countries. However, data from the Indian subcontinent are limited. We have estimated whole body radiation exposure to the radiopharmacist involved in the labeling of: (177)Lu-DOTATATE, (177)Lu-PSMA-617, and (177)Lu-EDTMP...
April 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28523582/first-in-human-radiation-dosimetry-of-68-ga-nodaga-rgdyk
#9
Silvano Gnesin, Periklis Mitsakis, Francesco Cicone, Emmanuel Deshayes, Vincent Dunet, Augusto F Gallino, Marek Kosinski, Sébastien Baechler, Franz Buchegger, David Viertl, John O Prior
BACKGROUND: Integrin-targeting radiopharmaceuticals have potential broad applications, spanning from cancer theranostics to cardiovascular diseases. We have previously reported preclinical dosimetry results of (68)Ga-NODAGA-RGDyK in mice. This study presents the first human dosimetry of (68)Ga-NODAGA-RGDyK in the five consecutive patients included in a clinical imaging protocol of carotid atherosclerotic plaques. Five male patients underwent whole-body time-of-flight (TOF) PET/CT scans 10, 60 and 120 min after tracer injection (200 MBq)...
December 2017: EJNMMI Research
https://www.readbyqxmd.com/read/28522742/evaluation-of-radiopharmaceutical-adverse-reaction-reports-to-the-british-nuclear-medicine-society-for-the-period-2007-to-2016
#10
Tracia-Gay Kennedy-Dixon, Maxine Gossell-Williams, Margaret Cooper, Moez Trabelsi, Sobhan Vinjamuri
Objective: This study sought to answer the calls for the restoration of reports of adverse reactions from the European Association of Nuclear Medicine. It assessed reports of adverse reactions to radiopharmaceuticals (ARRPs) that were submitted to the British Nuclear Medicine Society's (BNMS) Radiopharmaceutical Adverse Reactions and Product Defects online database during the period January 2007 to December 2016. Methodology: This investigation was a pharmacovigilance based, non-experimental, cross-sectional study aimed at finding the prevalence and association between radiopharmaceuticals and adverse reactions...
May 18, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28521118/automated-cassette-based-production-of-high-specific-activity-203-212-pb-peptide-based-theranostic-radiopharmaceuticals-for-image-guided-radionuclide-therapy-for-cancer
#11
Mengshi Li, Xiuli Zhang, Thomas P Quinn, Dongyoul Lee, Dijie Liu, Falk Kunkel, Brian E Zimmerman, Daniel McAlister, Keith Olewein, Yusuf Menda, Saed Mirzadeh, Roy Copping, Frances L Johnson, Michael K Schultz
A method for preparation of Pb-212 and Pb-203 labeled chelator-modified peptide-based radiopharmaceuticals for cancer imaging and radionuclide therapy has been developed and adapted for automated clinical production. Pre-concentration and isolation of radioactive Pb2+ from interfering metals in dilute hydrochloric acid was optimized using a commercially-available Pb-specific chromatography resin packed in disposable plastic columns. The pre-concentrated radioactive Pb2+ is eluted in NaOAc buffer directly to the reaction vessel containing chelator-modified peptides...
May 10, 2017: Applied Radiation and Isotopes
https://www.readbyqxmd.com/read/28514206/first-in-human-pet-ct-imaging-of-metastatic-neuroendocrine-neoplasms-with-cyclotron-produced-44-sc-dotatoc-a-proof-of-concept-study
#12
Aviral Singh, Nicholas P van der Meulen, Cristina Müller, Ingo Klette, Harshad R Kulkarni, Andreas Türler, Roger Schibli, Richard P Baum
(44)Sc is a promising positron emission tomography (PET) radionuclide (T1/2 = 4.04 hours, Eβ+average = 632 keV) and can be made available, using a cyclotron production route, in substantial quantities as a highly pure product. Herein, the authors report on a first-in-human PET/CT study using (44)Sc-DOTATOC prepared with cyclotron-produced (44)Sc. The production of (44)Sc was carried out through the (44)Ca(p,n)(44)Sc nuclear reaction at Paul Scherrer Institut, Switzerland. After separation, (44)Sc was shipped to Zentralklinik Bad Berka, Germany, where radiolabeling was performed, yielding radiochemically pure (44)Sc-DOTATOC...
May 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28512784/evaluation-of-aromatic-radiobromination-by-nucleophilic-substitution-using-diaryliodonium-salt-precursors
#13
Dong Zhou, Sung Hoon Kim, Wenhua Chu, Thomas Voller, John A Katzenellenbogen
Radiobromine labelled compounds can be used for positron emission tomography (PET) imaging (i.e. (76) Br) and for radiation therapy (i.e. (77) Br). However, the commonly used electrophilic substitution reaction using no-carrier-added (NCA) radiobromide does not always afford the desired product due to the high reactivity of the brominating intermediate. A nucleophilic substitution by bromide, such as radiobromination of iodonium precursors, provides an alternative route for the synthesis of bromo-radiopharmaceuticals...
May 17, 2017: Journal of Labelled Compounds & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28512575/new-leads-for-fragment-based-design-of-rhenium-technetium-radiopharmaceutical-agents
#14
Alice Brink, John R Helliwell
Multiple possibilities for the coordination of fac-[Re(CO)3(H2O)3](+) to a protein have been determined and include binding to Asp, Glu, Arg and His amino-acid residues as well as to the C-terminal carboxylate in the vicinity of Leu and Pro. The large number of rhenium metal complex binding sites that have been identified on specific residues thereby allow increased target identification for the design of future radiopharmaceuticals. The core experimental concept involved the use of state-of-art tuneable synchrotron radiation at the Diamond Light Source to optimize the rhenium anomalous dispersion signal to a large value (f'' of 12...
May 1, 2017: IUCrJ
https://www.readbyqxmd.com/read/28511061/uptake-of-ga-curcumin-derivatives-in-different-cancer-cell-lines-toward-the-development-of-new-potential-68-ga-labelled-curcuminoids-based-radiotracers-for-tumour-imaging
#15
Sara Rubagotti, Stefania Croci, Erika Ferrari, Giulia Orteca, Michele Iori, Pier C Capponi, Annibale Versari, Mattia Asti
Thanks to the ability to suppress the proliferation and to kill tumour cells, several studies have shown the anti-cancer effects of curcumin (CUR) and its derivatives, i.e. diacetylcurcumin (DAC) and bis-dehydroxycurcumin (bDHC). This study is focused onto the development of curcuminoid complexes with gallium-68 employed as potential new radio-labelled probes to detect neoplastic tissues through imaging techniques such as positron emission tomography. To this purpose, the uptake of three Ga-curcuminoid complexes, namely Ga(CUR)2(+), Ga(DAC)2(+), Ga(bDHC)2(+), by various tumour cell lines was compared with the uptake of the same compounds by normal human lymphocytes by flow cytometry using the intrinsic fluorescence of the curcuminoids...
May 10, 2017: Journal of Inorganic Biochemistry
https://www.readbyqxmd.com/read/28507199/whole-body-vibration-exercise-combined-with-an-extract-of-coriandrum-sativum-modify-some-biochemical-physiological-parameters-in-rats
#16
Éric Frederico, Andre Cardoso, Carlos Guimarães, Livia Almeida, Rosane de Figueiredo Neves, Danubia Sá-Caputo, Eloá Moreira-Marconi, Carla Dionello, Danielle Morel, Laisa Paineiras-Domingos, Rebeca Costa-Cavalcanti, Cintia Renata Souza Gonçalves, Adriano Arnóbio, Nasser Asad, Mario Bernardo-Filho
The aim of this study was to evaluate the effect of the association of WBV exercise with an aqueous extract of coriander on the biodistribution of the radiopharmaceutical sodium pertechnetate, on the concentration of some plasma biomarker, on the feed intake, on the body mass and on the stool consistency in rats. Rats were divided in four groups and submitted to different treatments for 40 days. The control group (CON) received deionized water. The group treated with coriander (COR) received the extract of coriander...
May 15, 2017: Bioscience Reports
https://www.readbyqxmd.com/read/28481794/spect-ct-detection-of-a-communicating-arachnoid-cyst-in-a-patient-with-normal-pressure-hydrocephalus
#17
Lisa Walker, Ali Gholamrezanezhad, Daniel Bucklan, Peter F Faulhaber, James K O'Donnell
A 59-year-old man with history of multiple sclerosis and residual sensory and motor dysfunction presented with progressive lower-extremity weakness, ataxic gait, and intermittent urinary incontinence. Brain MRI demonstrated volume loss with disproportionate ventricular dilatation, but no evidence of infarction or abnormal enhancement. Radionuclide cisternography showed early and persistent ventricular reflux, poor progression of radiopharmaceutical over convexities, and delayed clearance in a pattern consistent with normal pressure hydrocephalus...
May 6, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28477391/a-mix-and-use-approach-for-formulation-of-human-clinical-doses-of-177-lu-dotmp-at-hospital-radiopharmacy-for-management-of-pain-arising-from-skeletal-metastases
#18
Sudipta Chakraborty, K V Vimalnath, A Rajeswari, Rubel Chakravarty, H D Sarma, E Radhakrishnan, Kamaleshwaran K, Ajit S Shinto, Ashutosh Dash
Use of bone seeking radiopharmaceuticals is an established modality in the palliative care of pain due to skeletal metastases. (177) Lu-DOTMP is a promising radiopharmaceutical for this application owing to the ideally suited decay properties of (177) Lu and excellent thermodynamic stability and kinetic rigidity of the macrocyclic complex. The aim of the present study is to develop a robust and easily adaptable protocol for formulation of clinical doses of (177) Lu-DOTMP at hospital radiopharmacy. After extensive radiochemical studies, an optimized strategy for formulation of clinical doses of (177) Lu-DOTMP was developed which involves simple mixing of ~3...
May 5, 2017: Journal of Labelled Compounds & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28474140/comparison-of-psma-hbed-and-psma-i-t-as-diagnostic-agents-in-prostate-carcinoma
#19
Michael McCarthy, Tiffany Langton, Divesh Kumar, Andrew Campbell
PURPOSE: Gallium(68)-labelled prostate-specific membrane antigen (PSMA) radiopharmaceuticals can be used to detect prostate cancer (PCa) cells due the their over expression of PSMA. The (68)Ga HBED-PSMA (PSMA-HBED) ligand has been most widely used and can be considered the current gold standard agent. Further PSMA ligands based on the DOTAGA and DOTA conjugates have more recently been developed. These agents (PSMA-I&T and PSMA-617) have potential theranostic capabilities as they can be conjugated with therapeutic radioisotopes...
May 4, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28469335/pediatric-osteosarcoma-an-updated-review
#20
REVIEW
Shachi Jain Taran, Rakesh Taran, Nagraj B Malipatil
Osteosarcoma (OS), the most common type of primary malignant bone tumor, is defined by the presence of malignant mesenchymal cells producing osteoid or immature bone. The peak incidence of the most frequent type of OS, i.e., high-grade central OS, occurs in the second decade of life during the adolescent growth spurt. Most patients suffer from the pain and swelling in the involved region and, usually, seek medical attention. Diagnosis is carried out by conventional radiographs, computed tomography, and magnetic resonance image (MRI)...
January 2017: Indian Journal of Medical and Paediatric Oncology
keyword
keyword
29071
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"